NO316021B1 - Nye pyridazinderivater, anveldelse derav og medikamenter inneholdende dissesom effektive ingredienser - Google Patents
Nye pyridazinderivater, anveldelse derav og medikamenter inneholdende dissesom effektive ingredienser Download PDFInfo
- Publication number
- NO316021B1 NO316021B1 NO20002169A NO20002169A NO316021B1 NO 316021 B1 NO316021 B1 NO 316021B1 NO 20002169 A NO20002169 A NO 20002169A NO 20002169 A NO20002169 A NO 20002169A NO 316021 B1 NO316021 B1 NO 316021B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- methoxyphenyl
- bis
- pyndazin
- preparation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 20
- 239000004615 ingredient Substances 0.000 title claims description 3
- 150000004892 pyridazines Chemical class 0.000 title abstract description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 89
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 125000001424 substituent group Chemical group 0.000 claims abstract description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 17
- 125000005843 halogen group Chemical group 0.000 claims abstract description 16
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims abstract description 14
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 11
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims abstract description 9
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract description 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 9
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract description 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 264
- 238000002360 preparation method Methods 0.000 claims description 217
- -1 piperazino Chemical group 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 7
- 102000000589 Interleukin-1 Human genes 0.000 claims description 6
- 108010002352 Interleukin-1 Proteins 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 208000023589 ischemic disease Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- HEUAVAATAFEENP-UHFFFAOYSA-N 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CC=C1 HEUAVAATAFEENP-UHFFFAOYSA-N 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- ZKRCUQZNYGDTTG-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)prop-2-enyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC=CC1=CC=C(Cl)C=C1 ZKRCUQZNYGDTTG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- SFGDYKRZXPJJNQ-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-propan-2-ylpyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(C(C)C)N=C1C1=CC=C(OC)C=C1 SFGDYKRZXPJJNQ-UHFFFAOYSA-N 0.000 claims 1
- 230000034401 positive regulation of interleukin-1 beta production Effects 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 356
- 238000005160 1H NMR spectroscopy Methods 0.000 description 194
- 238000000034 method Methods 0.000 description 150
- 238000002844 melting Methods 0.000 description 149
- 230000008018 melting Effects 0.000 description 149
- 239000007858 starting material Substances 0.000 description 148
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 84
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 80
- 239000002904 solvent Substances 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 55
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 45
- 239000000203 mixture Substances 0.000 description 44
- 239000000243 solution Substances 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
- 239000000741 silica gel Substances 0.000 description 41
- 229910002027 silica gel Inorganic materials 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 239000000843 powder Substances 0.000 description 24
- 239000000126 substance Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000013078 crystal Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- 239000012267 brine Substances 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 239000002585 base Substances 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 16
- DJNBDDQYBFFRHG-UHFFFAOYSA-N 3,4-bis(4-methoxyphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)NN=C1C1=CC=C(OC)C=C1 DJNBDDQYBFFRHG-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 235000011181 potassium carbonates Nutrition 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 11
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 10
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 238000004237 preparative chromatography Methods 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 125000004185 ester group Chemical group 0.000 description 7
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 7
- 229940015043 glyoxal Drugs 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- PZOUYAPZFJOWJT-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-(4-methylsulfanylphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(SC)=CC=C1C1=NNC(=O)C=C1C1=CC=C(Cl)C=C1 PZOUYAPZFJOWJT-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 230000019189 interleukin-1 beta production Effects 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- LSKFEVSKQANAJP-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfanylphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(SC)=CC=C1C1=NNC(=O)C=C1C1=CC=C(F)C=C1 LSKFEVSKQANAJP-UHFFFAOYSA-N 0.000 description 5
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000013067 intermediate product Substances 0.000 description 5
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- CLZRDHUBODXICN-UHFFFAOYSA-N 1-chloro-4-(3-chloroprop-1-enyl)benzene Chemical compound ClCC=CC1=CC=C(Cl)C=C1 CLZRDHUBODXICN-UHFFFAOYSA-N 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- DORHFVFUWAQNGE-UHFFFAOYSA-N 3-(4-methoxyphenyl)-4-pyridin-4-yl-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=NNC(=O)C=C1C1=CC=NC=C1 DORHFVFUWAQNGE-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 3
- SCYWFASJZCRIMI-UHFFFAOYSA-N 2-(2-hydroxyethyl)-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(CCO)N=C1C1=CC=C(OC)C=C1 SCYWFASJZCRIMI-UHFFFAOYSA-N 0.000 description 3
- WOSRMEPOABNNKH-UHFFFAOYSA-N 2-benzyl-5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1=CC=CC=C1 WOSRMEPOABNNKH-UHFFFAOYSA-N 0.000 description 3
- QBZCDOXPVUZTAX-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)NN=C1C1=CC=C(OC)C(OC)=C1 QBZCDOXPVUZTAX-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- 241000586542 Aonidiella citrina Species 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- ZVTQWXCKQTUVPY-UHFFFAOYSA-N chloromethylcyclopropane Chemical compound ClCC1CC1 ZVTQWXCKQTUVPY-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- GFELZIQHBWTYQB-UHFFFAOYSA-N ethyl 3,4-bis(3-fluoro-4-methoxyphenyl)-4-oxobutanoate Chemical compound C=1C=C(OC)C(F)=CC=1C(CC(=O)OCC)C(=O)C1=CC=C(OC)C(F)=C1 GFELZIQHBWTYQB-UHFFFAOYSA-N 0.000 description 3
- UEPLGJHHZUYWFV-UHFFFAOYSA-N ethyl 3-(3-fluoro-4-methoxyphenyl)-4-(4-methoxyphenyl)-4-oxobutanoate Chemical compound C=1C=C(OC)C(F)=CC=1C(CC(=O)OCC)C(=O)C1=CC=C(OC)C=C1 UEPLGJHHZUYWFV-UHFFFAOYSA-N 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- WORJEOGGNQDSOE-ASTXPPQBSA-N trichloro(deuterio)methane;trideuterio(deuteriooxy)methane Chemical compound [2H]C(Cl)(Cl)Cl.[2H]OC([2H])([2H])[2H] WORJEOGGNQDSOE-ASTXPPQBSA-N 0.000 description 3
- SMIXCMBLNFEUSS-UHFFFAOYSA-N 1,2-bis(3-fluoro-4-methoxyphenyl)ethanone Chemical compound C1=C(F)C(OC)=CC=C1CC(=O)C1=CC=C(OC)C(F)=C1 SMIXCMBLNFEUSS-UHFFFAOYSA-N 0.000 description 2
- XTSWQXIWFZTMJR-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)-2-phenylethanone Chemical compound C1=CC(SC)=CC=C1C(=O)CC1=CC=CC=C1 XTSWQXIWFZTMJR-UHFFFAOYSA-N 0.000 description 2
- JIXDOBAQOWOUPA-UHFFFAOYSA-N 1-fluoro-2-methoxybenzene Chemical compound COC1=CC=CC=C1F JIXDOBAQOWOUPA-UHFFFAOYSA-N 0.000 description 2
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 2
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 2
- NKOOOGLVZHMYNJ-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)-1-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=C(OC)C(F)=C1 NKOOOGLVZHMYNJ-UHFFFAOYSA-N 0.000 description 2
- VURNBRZIFABCRU-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1F VURNBRZIFABCRU-UHFFFAOYSA-N 0.000 description 2
- MMWCHRKSYDTYQU-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(4-methylsulfanylphenyl)ethanone Chemical compound C1=CC(SC)=CC=C1C(=O)CC1=CC=C(Cl)C=C1 MMWCHRKSYDTYQU-UHFFFAOYSA-N 0.000 description 2
- BKZXEVNPUKCVRB-UHFFFAOYSA-N 2-(cyclopropylmethyl)-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1CC1 BKZXEVNPUKCVRB-UHFFFAOYSA-N 0.000 description 2
- WBYUBRFBKBZZAH-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1=CC=C(Cl)C=C1Cl WBYUBRFBKBZZAH-UHFFFAOYSA-N 0.000 description 2
- LKQRMXDKUZJSMK-UHFFFAOYSA-N 2-[[4-(dimethylamino)phenyl]methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(N(C)C)C=C1 LKQRMXDKUZJSMK-UHFFFAOYSA-N 0.000 description 2
- APBMTOIOMFJFEB-UHFFFAOYSA-N 2-benzyl-5,6-bis(4-methoxyphenyl)pyridazine-3-thione Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=S)N1CC1=CC=CC=C1 APBMTOIOMFJFEB-UHFFFAOYSA-N 0.000 description 2
- MXWPSXGXEIIJGB-UHFFFAOYSA-N 2-ethyl-5,6-bis(3-fluoro-4-methoxyphenyl)pyridazin-3-one Chemical compound C=1C=C(OC)C(F)=CC=1C1=CC(=O)N(CC)N=C1C1=CC=C(OC)C(F)=C1 MXWPSXGXEIIJGB-UHFFFAOYSA-N 0.000 description 2
- ROLCKZSWPSXALR-UHFFFAOYSA-N 2-hydroxy-3,4-bis(4-methoxyphenyl)-4-oxobutanoic acid Chemical compound C1=CC(OC)=CC=C1C(C(O)C(O)=O)C(=O)C1=CC=C(OC)C=C1 ROLCKZSWPSXALR-UHFFFAOYSA-N 0.000 description 2
- SJYWYLFZYULIQG-UHFFFAOYSA-N 3,4-bis(3-fluoro-4-methoxyphenyl)-1h-pyridazin-6-one Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(=O)NN=C1C1=CC=C(OC)C(F)=C1 SJYWYLFZYULIQG-UHFFFAOYSA-N 0.000 description 2
- WFLXWJDDIFYPSG-UHFFFAOYSA-N 3-(3-fluoro-4-methoxyphenyl)-4-(4-methoxyphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)NN=C1C1=CC=C(OC)C(F)=C1 WFLXWJDDIFYPSG-UHFFFAOYSA-N 0.000 description 2
- ANFMIAKFUSYBHY-UHFFFAOYSA-N 4-(3-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=NNC(=O)C=C1C1=CC=C(OC)C(F)=C1 ANFMIAKFUSYBHY-UHFFFAOYSA-N 0.000 description 2
- AQEIHATWBLFFRG-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-(4-methylsulfanylphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(SC)=CC=C1C1=NNC(=O)CC1C1=CC=C(Cl)C=C1 AQEIHATWBLFFRG-UHFFFAOYSA-N 0.000 description 2
- NRPFNQUDKRYCNX-UHFFFAOYSA-N 4-methoxyphenylacetic acid Chemical compound COC1=CC=C(CC(O)=O)C=C1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 2
- PSQCMQGRKRSPJM-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-(pyridin-3-ylmethyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=CN=C1 PSQCMQGRKRSPJM-UHFFFAOYSA-N 0.000 description 2
- PPMNTODHGPICES-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[(2,4-dichlorophenyl)methyl]-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=C(Cl)C=C1Cl PPMNTODHGPICES-UHFFFAOYSA-N 0.000 description 2
- CWDNMKHXLDKLER-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[(2,4-difluorophenyl)methyl]-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=C(F)C=C1F CWDNMKHXLDKLER-UHFFFAOYSA-N 0.000 description 2
- BHDSDVWWGXIOEP-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C=C(C=2C=CC(F)=CC=2)C(C=2C=CC(SC)=CC=2)=N1 BHDSDVWWGXIOEP-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000005905 mesyloxy group Chemical group 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BFRWMZNFUHINEW-UHFFFAOYSA-N methyl 3-(4-chlorophenyl)-4-(4-methylsulfanylphenyl)-4-oxobutanoate Chemical compound C=1C=C(Cl)C=CC=1C(CC(=O)OC)C(=O)C1=CC=C(SC)C=C1 BFRWMZNFUHINEW-UHFFFAOYSA-N 0.000 description 2
- HSIRBZKSNDBENI-UHFFFAOYSA-N methyl 4-(4-methylsulfanylphenyl)-4-oxo-3-phenylbutanoate Chemical compound C=1C=CC=CC=1C(CC(=O)OC)C(=O)C1=CC=C(SC)C=C1 HSIRBZKSNDBENI-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- UQFSVBXCNGCBBW-UHFFFAOYSA-M tetraethylammonium iodide Chemical compound [I-].CC[N+](CC)(CC)CC UQFSVBXCNGCBBW-UHFFFAOYSA-M 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- SICBLYCPRWNHHP-UHFFFAOYSA-N 1,2-bis(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(OC)C=C1 SICBLYCPRWNHHP-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- LUCJEOWFMRABMA-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-2-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(OC)C(OC)=C1 LUCJEOWFMRABMA-UHFFFAOYSA-N 0.000 description 1
- MZZMSNXSGCFXKA-UHFFFAOYSA-N 1-(3-fluoro-4-methoxyphenyl)-2-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(OC)C(F)=C1 MZZMSNXSGCFXKA-UHFFFAOYSA-N 0.000 description 1
- PLALKSRAHVYFOH-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-phenylethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=CC=C1 PLALKSRAHVYFOH-UHFFFAOYSA-N 0.000 description 1
- FQOSOMYMMDPZAA-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-pyridin-4-ylethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=NC=C1 FQOSOMYMMDPZAA-UHFFFAOYSA-N 0.000 description 1
- JECUZQLBQKNEMW-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)ethanone Chemical compound CSC1=CC=C(C(C)=O)C=C1 JECUZQLBQKNEMW-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- GSYCXDGNSNVUTA-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=C(Cl)C=C1 GSYCXDGNSNVUTA-UHFFFAOYSA-N 0.000 description 1
- ZRDPBDKPWLKWKR-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-(4-methylsulfanylphenyl)ethanone Chemical compound C1=CC(SC)=CC=C1C(=O)CC1=CC=C(F)C=C1 ZRDPBDKPWLKWKR-UHFFFAOYSA-N 0.000 description 1
- CYFDWDOOXOKYTM-UHFFFAOYSA-N 2-(cyclopentylmethyl)-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1CCCC1 CYFDWDOOXOKYTM-UHFFFAOYSA-N 0.000 description 1
- IYDIOAVPZGPAID-UHFFFAOYSA-N 2-(cyclopentylmethyl)-6-(4-methoxyphenyl)-5-pyridin-4-ylpyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=CC1=O)C=2C=CN=CC=2)=NN1CC1CCCC1 IYDIOAVPZGPAID-UHFFFAOYSA-N 0.000 description 1
- PKADNCMHLQFXJC-UHFFFAOYSA-N 2-(cyclopropylmethyl)-5,6-bis(4-methoxyphenyl)pyridazine-3-thione Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=S)N1CC1CC1 PKADNCMHLQFXJC-UHFFFAOYSA-N 0.000 description 1
- WNPSGLPXGRZKQS-UHFFFAOYSA-N 2-(cyclopropylmethyl)-5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1CC1 WNPSGLPXGRZKQS-UHFFFAOYSA-N 0.000 description 1
- PQTQWTGSVKLKEN-UHFFFAOYSA-N 2-(cyclopropylmethyl)-5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)pyridazine-3-thione Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=S)C=2C=CC(F)=CC=2)=NN1CC1CC1 PQTQWTGSVKLKEN-UHFFFAOYSA-N 0.000 description 1
- XNXJPUSSLLZQSX-UHFFFAOYSA-N 2-(cyclopropylmethyl)-6-(3-fluoro-4-methoxyphenyl)-5-(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=C(F)C(OC)=CC=2)=CC(=O)N1CC1CC1 XNXJPUSSLLZQSX-UHFFFAOYSA-N 0.000 description 1
- HOZCMLDTHOXMMO-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(Cl)C=C1Cl HOZCMLDTHOXMMO-UHFFFAOYSA-N 0.000 description 1
- HREKPOZKLXSECK-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazine-3-thione Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=S)N1CC1=CC=C(Cl)C=C1Cl HREKPOZKLXSECK-UHFFFAOYSA-N 0.000 description 1
- UBBMJFDIFJHCHE-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)pyridazine-3-thione Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=S)C=2C=CC(F)=CC=2)=NN1CC1=CC=C(Cl)C=C1Cl UBBMJFDIFJHCHE-UHFFFAOYSA-N 0.000 description 1
- NMECIEQKRSAKGA-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-6-(3,4-dimethoxyphenyl)-5-(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=C(OC)C(OC)=CC=2)=CC(=O)N1CC1=CC=C(Cl)C=C1Cl NMECIEQKRSAKGA-UHFFFAOYSA-N 0.000 description 1
- HYSKZBIPFYPECW-UHFFFAOYSA-N 2-[(2,4-difluorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(F)C=C1F HYSKZBIPFYPECW-UHFFFAOYSA-N 0.000 description 1
- CZYKMURJZNENDD-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=C(Cl)C=CC=C1Cl CZYKMURJZNENDD-UHFFFAOYSA-N 0.000 description 1
- DOQFSKJPZOAIBK-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(Cl)C(Cl)=C1 DOQFSKJPZOAIBK-UHFFFAOYSA-N 0.000 description 1
- SRZYHDXKYGVKNZ-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(F)C(F)=C1 SRZYHDXKYGVKNZ-UHFFFAOYSA-N 0.000 description 1
- QBCGYCJCTATGLU-UHFFFAOYSA-N 2-[(3-fluoro-4-methoxyphenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(OC)C(F)=C1 QBCGYCJCTATGLU-UHFFFAOYSA-N 0.000 description 1
- IOCUDCMCNDKKKI-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(N)C=C1 IOCUDCMCNDKKKI-UHFFFAOYSA-N 0.000 description 1
- ZZXQPJDRCSMCCC-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(Cl)C=C1 ZZXQPJDRCSMCCC-UHFFFAOYSA-N 0.000 description 1
- KTUIUURANQJFED-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C(F)C=C1 KTUIUURANQJFED-UHFFFAOYSA-N 0.000 description 1
- OZSUZUSKUQOUPT-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)ethyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CCC1=CC=C(OC)C(OC)=C1 OZSUZUSKUQOUPT-UHFFFAOYSA-N 0.000 description 1
- FNYBGSCNVGLZQH-UHFFFAOYSA-N 2-[3-(2,4-dichlorophenyl)prop-2-enyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC=CC1=CC=C(Cl)C=C1Cl FNYBGSCNVGLZQH-UHFFFAOYSA-N 0.000 description 1
- XHHUONMZWZTSGS-UHFFFAOYSA-N 2-[3-(2,4-difluorophenyl)prop-2-enyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC=CC1=CC=C(F)C=C1F XHHUONMZWZTSGS-UHFFFAOYSA-N 0.000 description 1
- HCCARKPYVPVNMC-UHFFFAOYSA-N 2-[3-(2,4-difluorophenyl)prop-2-enyl]-5,6-bis(4-methoxyphenyl)pyridazine-3-thione Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=S)N1CC=CC1=CC=C(F)C=C1F HCCARKPYVPVNMC-UHFFFAOYSA-N 0.000 description 1
- XUCDXJJWDPGPBL-UHFFFAOYSA-N 2-[3-(2,4-difluorophenyl)prop-2-enyl]-5-(4-fluorophenyl)-6-(4-methylsulfinylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC=CC1=CC=C(F)C=C1F XUCDXJJWDPGPBL-UHFFFAOYSA-N 0.000 description 1
- SNMHVILVRWMOSQ-UHFFFAOYSA-N 2-[3-(2,4-difluorophenyl)propyl]-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CCCC1=CC=C(F)C=C1F SNMHVILVRWMOSQ-UHFFFAOYSA-N 0.000 description 1
- MPQPWJZLCNDSOI-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)prop-2-enyl]-5,6-bis(3-fluoro-4-methoxyphenyl)pyridazin-3-one Chemical compound C1=C(F)C(OC)=CC=C1C(C(=N1)C=2C=C(F)C(OC)=CC=2)=CC(=O)N1CC=CC1=CC=C(Cl)C=C1 MPQPWJZLCNDSOI-UHFFFAOYSA-N 0.000 description 1
- QQSQRBVJZREGAA-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)prop-2-enyl]-6-(3-fluoro-4-methoxyphenyl)-5-(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=C(F)C(OC)=CC=2)=CC(=O)N1CC=CC1=CC=C(Cl)C=C1 QQSQRBVJZREGAA-UHFFFAOYSA-N 0.000 description 1
- RVACAWSOYJCCGW-UHFFFAOYSA-N 2-benzyl-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=CC=C1 RVACAWSOYJCCGW-UHFFFAOYSA-N 0.000 description 1
- NMVWRVXNTUZIRT-UHFFFAOYSA-N 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CC=C1 NMVWRVXNTUZIRT-UHFFFAOYSA-N 0.000 description 1
- HNOUHKPVSRBCMS-UHFFFAOYSA-N 2-benzyl-5-(4-fluorophenyl)-6-(4-methylsulfinylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1=CC=CC=C1 HNOUHKPVSRBCMS-UHFFFAOYSA-N 0.000 description 1
- YKGWPKRQHSZIDL-UHFFFAOYSA-N 2-benzyl-6-(4-methoxyphenyl)-5-pyridin-4-ylpyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=CC1=O)C=2C=CN=CC=2)=NN1CC1=CC=CC=C1 YKGWPKRQHSZIDL-UHFFFAOYSA-N 0.000 description 1
- DINIBVKVQYHFRZ-UHFFFAOYSA-N 2-benzyl-6-(4-methylsulfanylphenyl)-5-phenylpyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC=CC=2)=NN1CC1=CC=CC=C1 DINIBVKVQYHFRZ-UHFFFAOYSA-N 0.000 description 1
- PAQFYSIVYBERJR-UHFFFAOYSA-N 2-cyclopentyl-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(C2CCCC2)N=C1C1=CC=C(OC)C=C1 PAQFYSIVYBERJR-UHFFFAOYSA-N 0.000 description 1
- UFYYAZUWJJKGJZ-UHFFFAOYSA-N 2-cyclopropyl-5,6-bis(4-methoxyphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(C2CC2)N=C1C1=CC=C(OC)C=C1 UFYYAZUWJJKGJZ-UHFFFAOYSA-N 0.000 description 1
- SKZVVZGPNYCUMJ-UHFFFAOYSA-N 2-ethyl-5-(3-fluoro-4-methoxyphenyl)-6-(4-methoxyphenyl)pyridazin-3-one Chemical compound C=1C=C(OC)C(F)=CC=1C1=CC(=O)N(CC)N=C1C1=CC=C(OC)C=C1 SKZVVZGPNYCUMJ-UHFFFAOYSA-N 0.000 description 1
- XJFSDAQUZXSRMY-UHFFFAOYSA-N 2-hydroxy-4-oxobutanoic acid Chemical class OC(=O)C(O)CC=O XJFSDAQUZXSRMY-UHFFFAOYSA-N 0.000 description 1
- XQNJNOCGEQCHAA-UHFFFAOYSA-N 2-phenoxy-2h-chromene Chemical compound O1C2=CC=CC=C2C=CC1OC1=CC=CC=C1 XQNJNOCGEQCHAA-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LZJLXDNGANKYIE-UHFFFAOYSA-N 3,4-diphenylpyridazine Chemical compound C1=CC=CC=C1C1=CC=NN=C1C1=CC=CC=C1 LZJLXDNGANKYIE-UHFFFAOYSA-N 0.000 description 1
- DNXUGBMARDFRGG-UHFFFAOYSA-N 3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound O=C1C=CC(=O)C(C#N)=C1C#N DNXUGBMARDFRGG-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BMXCIGBWJZLSLY-UHFFFAOYSA-N 3-(3-fluoro-4-methoxyphenyl)-4-(4-methoxyphenyl)-1h-pyridazine-6-thione Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)NN=C1C1=CC=C(OC)C(F)=C1 BMXCIGBWJZLSLY-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- UFYZGFFNUWAZSO-UHFFFAOYSA-N 3-[3,4-bis(4-methoxyphenyl)-6-oxopyridazin-1-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)N(CCC(O)=O)N=C1C1=CC=C(OC)C=C1 UFYZGFFNUWAZSO-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- KSAPOVNSSQTEPN-UHFFFAOYSA-N 4-(3-fluoro-4-methoxyphenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=NNC(=O)CC1C1=CC=C(OC)C(F)=C1 KSAPOVNSSQTEPN-UHFFFAOYSA-N 0.000 description 1
- NSEPDNQFIRJZOZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-(4-methoxyphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C1=NNC(=O)C=C1C1=CC=C(Cl)C=C1 NSEPDNQFIRJZOZ-UHFFFAOYSA-N 0.000 description 1
- FQLKJUXTAADXIK-UHFFFAOYSA-N 4-(4-chlorophenyl)-3-(4-methylsulfonylphenyl)-1h-pyridazin-6-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NNC(=O)C=C1C1=CC=C(Cl)C=C1 FQLKJUXTAADXIK-UHFFFAOYSA-N 0.000 description 1
- PTJWWMIWAHNSPI-UHFFFAOYSA-N 4-(4-fluorophenyl)-3-(4-methylsulfanylphenyl)-1h-pyridazine-6-thione Chemical compound C1=CC(SC)=CC=C1C1=NNC(=S)C=C1C1=CC=C(F)C=C1 PTJWWMIWAHNSPI-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- CDPKJZJVTHSESZ-UHFFFAOYSA-N 4-chlorophenylacetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1 CDPKJZJVTHSESZ-UHFFFAOYSA-N 0.000 description 1
- KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical compound OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 1
- FBZSYRLNWSPRBX-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-(3-phenylpropyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CCCC1=CC=CC=C1 FBZSYRLNWSPRBX-UHFFFAOYSA-N 0.000 description 1
- UEAPARQQNQEZFO-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-(pyridin-4-ylmethyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=NC=C1 UEAPARQQNQEZFO-UHFFFAOYSA-N 0.000 description 1
- XEBIVGHVRAFVEZ-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[(2,4,6-trichlorophenyl)methyl]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=C(Cl)C=C(Cl)C=C1Cl XEBIVGHVRAFVEZ-UHFFFAOYSA-N 0.000 description 1
- MGQASQXSRXQQOL-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[(3,4,5-trimethoxyphenyl)methyl]pyridazine-3-thione Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=S)N1CC1=CC(OC)=C(OC)C(OC)=C1 MGQASQXSRXQQOL-UHFFFAOYSA-N 0.000 description 1
- MGRMLYYSMVRZSO-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[(4-nitrophenyl)methyl]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC1=CC=C([N+]([O-])=O)C=C1 MGRMLYYSMVRZSO-UHFFFAOYSA-N 0.000 description 1
- GATKMOYOYVJLCQ-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC(=O)N1CCN(C)CC1 GATKMOYOYVJLCQ-UHFFFAOYSA-N 0.000 description 1
- FQSUHAINRMQIDB-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[2-(4-methylpiperazin-1-yl)ethyl]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CCN1CCN(C)CC1 FQSUHAINRMQIDB-UHFFFAOYSA-N 0.000 description 1
- HHNASKVMIVZZPP-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[3-(4-methylphenyl)prop-2-enyl]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CC=CC1=CC=C(C)C=C1 HHNASKVMIVZZPP-UHFFFAOYSA-N 0.000 description 1
- SBKVZDDPJOFVOG-UHFFFAOYSA-N 5,6-bis(4-methoxyphenyl)-2-[3-(4-methylphenyl)propyl]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=N1)C=2C=CC(OC)=CC=2)=CC(=O)N1CCCC1=CC=C(C)C=C1 SBKVZDDPJOFVOG-UHFFFAOYSA-N 0.000 description 1
- QTQLWTRISPYTJF-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-(cyclopropylmethyl)-6-(4-methylsulfanylphenyl)pyridazine-3-thione Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=S)C=2C=CC(Cl)=CC=2)=NN1CC1CC1 QTQLWTRISPYTJF-UHFFFAOYSA-N 0.000 description 1
- QFWDCHZOWMFGPV-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)-2-(3-phenylpropyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CCCC1=CC=CC=C1 QFWDCHZOWMFGPV-UHFFFAOYSA-N 0.000 description 1
- QUOSYCVUEFMEBC-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)-2-(pyridin-3-ylmethyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CN=C1 QUOSYCVUEFMEBC-UHFFFAOYSA-N 0.000 description 1
- MODUYMPUAORGNH-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(4-methylsulfonylphenyl)-2-(3-phenylpropyl)pyridazin-3-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CCCC1=CC=CC=C1 MODUYMPUAORGNH-UHFFFAOYSA-N 0.000 description 1
- AFDMITPGHICZKL-UHFFFAOYSA-N 5-(4-chlorophenyl)-6-(4-methylsulfonylphenyl)-2-(pyridin-3-ylmethyl)pyridazin-3-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(Cl)=CC=2)=NN1CC1=CC=CN=C1 AFDMITPGHICZKL-UHFFFAOYSA-N 0.000 description 1
- OTXDUEWRXWOXEF-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-6-(4-methylsulfinylphenyl)pyridazin-3-one Chemical compound C1=CC(S(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1=CC=C(F)C=C1 OTXDUEWRXWOXEF-UHFFFAOYSA-N 0.000 description 1
- DOBCCYNMHQPSEN-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-6-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C=C(C=2C=CC(F)=CC=2)C(C=2C=CC(=CC=2)S(C)(=O)=O)=N1 DOBCCYNMHQPSEN-UHFFFAOYSA-N 0.000 description 1
- OGKLXKWFPCETGA-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)-2-(2,2,2-trifluoroethyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C1=NN(CC(F)(F)F)C(=O)C=C1C1=CC=C(F)C=C1 OGKLXKWFPCETGA-UHFFFAOYSA-N 0.000 description 1
- OBZWIEIWRBCOJW-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylsulfanylphenyl)-2-(pyridin-3-ylmethyl)pyridazin-3-one Chemical compound C1=CC(SC)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1=CC=CN=C1 OBZWIEIWRBCOJW-UHFFFAOYSA-N 0.000 description 1
- UBOUXIVEDKZTMG-UHFFFAOYSA-N 5-(4-fluorophenyl)-6-(4-methylsulfinylphenyl)-2-(pyridin-4-ylmethyl)pyridazin-3-one Chemical compound C1=CC(S(=O)C)=CC=C1C(C(=CC1=O)C=2C=CC(F)=CC=2)=NN1CC1=CC=NC=C1 UBOUXIVEDKZTMG-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- VUTQNUPNGLIJRW-UHFFFAOYSA-N 6-(4-methoxyphenyl)-2-(3-phenylprop-2-enyl)-5-pyridin-4-ylpyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=CC1=O)C=2C=CN=CC=2)=NN1CC=CC1=CC=CC=C1 VUTQNUPNGLIJRW-UHFFFAOYSA-N 0.000 description 1
- KCOQREBOOZDLJA-UHFFFAOYSA-N 6-(4-methoxyphenyl)-5-phenyl-2-(3-phenylprop-2-enyl)pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1C(C(=CC1=O)C=2C=CC=CC=2)=NN1CC=CC1=CC=CC=C1 KCOQREBOOZDLJA-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101150046236 CNR1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229920006358 Fluon Polymers 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 206010023025 Ischaemic hepatitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MSJHOJKVMMEMNX-UHFFFAOYSA-N benzylhydrazine;hydron;dichloride Chemical compound Cl.Cl.NNCC1=CC=CC=C1 MSJHOJKVMMEMNX-UHFFFAOYSA-N 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- ONPSRCNNSZSSMH-UHFFFAOYSA-N chloroform;hexane;methanol Chemical compound OC.ClC(Cl)Cl.CCCCCC ONPSRCNNSZSSMH-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- UCPFREPFIWVFSJ-UHFFFAOYSA-N chloroform;propan-2-one;hydrate Chemical compound O.CC(C)=O.ClC(Cl)Cl UCPFREPFIWVFSJ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- UPPBZOFWXKFRHI-UHFFFAOYSA-N dichloromethane;hexane;methanol Chemical compound OC.ClCCl.CCCCCC UPPBZOFWXKFRHI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- RYHKORAYABGNGV-UHFFFAOYSA-N ethyl 3-(4-chlorophenyl)-4-(4-methylsulfanylphenyl)-4-oxobutanoate Chemical compound C=1C=C(Cl)C=CC=1C(CC(=O)OCC)C(=O)C1=CC=C(SC)C=C1 RYHKORAYABGNGV-UHFFFAOYSA-N 0.000 description 1
- ZCLGVXACCAZJOX-UHFFFAOYSA-N ethyl 3-chloropropanoate Chemical compound CCOC(=O)CCCl ZCLGVXACCAZJOX-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- YOERYAYLBGZZFR-UHFFFAOYSA-N methyl 3-(4-fluorophenyl)-4-(4-methylsulfanylphenyl)-4-oxobutanoate Chemical compound C=1C=C(F)C=CC=1C(CC(=O)OC)C(=O)C1=CC=C(SC)C=C1 YOERYAYLBGZZFR-UHFFFAOYSA-N 0.000 description 1
- HGMOFXKSRDWRAD-UHFFFAOYSA-N methyl 4-[[3,4-bis(4-methoxyphenyl)-6-oxopyridazin-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)C=C(C=2C=CC(OC)=CC=2)C(C=2C=CC(OC)=CC=2)=N1 HGMOFXKSRDWRAD-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- TVPRCLHSULCNLV-UHFFFAOYSA-N pyridazin-3-one Chemical compound O=C1C=CC=N[N]1 TVPRCLHSULCNLV-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 1
- GOCADJZGBKCYNV-UHFFFAOYSA-N tert-butyl 3-[(4-methylphenyl)sulfonyloxymethyl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1CN(C(=O)OC(C)(C)C)CCC1 GOCADJZGBKCYNV-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31813297 | 1997-11-19 | ||
JP31813397A JP3999861B2 (ja) | 1997-11-19 | 1997-11-19 | 新規ピリダジン誘導体及びこれを有効成分とする医薬 |
PCT/JP1998/005023 WO1999025697A1 (fr) | 1997-11-19 | 1998-11-09 | Nouveaux derives de pyridazine et medicaments contenant ces composes comme principe actif |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20002169D0 NO20002169D0 (no) | 2000-04-27 |
NO20002169L NO20002169L (no) | 2000-05-18 |
NO316021B1 true NO316021B1 (no) | 2003-12-01 |
Family
ID=26569260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20002169A NO316021B1 (no) | 1997-11-19 | 2000-04-27 | Nye pyridazinderivater, anveldelse derav og medikamenter inneholdende dissesom effektive ingredienser |
Country Status (21)
Country | Link |
---|---|
US (11) | US6348468B1 (es) |
EP (2) | EP1043317B1 (es) |
KR (1) | KR100626605B1 (es) |
CN (1) | CN1142148C (es) |
AT (1) | ATE428700T1 (es) |
AU (1) | AU738595B2 (es) |
BR (1) | BR9813998A (es) |
CA (1) | CA2307111C (es) |
DE (1) | DE69840755D1 (es) |
DK (1) | DK1043317T3 (es) |
ES (1) | ES2324126T3 (es) |
HK (1) | HK1032969A1 (es) |
HU (1) | HUP0100059A3 (es) |
ID (1) | ID24166A (es) |
MX (1) | MXPA00004955A (es) |
NO (1) | NO316021B1 (es) |
NZ (1) | NZ504045A (es) |
PT (1) | PT1043317E (es) |
RU (1) | RU2209813C2 (es) |
TW (1) | TW502025B (es) |
WO (1) | WO1999025697A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2307111C (en) * | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
TW587079B (en) * | 1998-09-25 | 2004-05-11 | Almirall Prodesfarma Ag | 2-phenylpyran-4-one derivatives |
JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−3−オン誘導体及びこれを含有する医薬 |
ES2162731B1 (es) * | 1999-06-04 | 2003-02-16 | Faes Fabrica Espanola De Produ | Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas. |
PE20011333A1 (es) | 2000-03-16 | 2002-01-16 | Almirall Prodesfarma Ag | Derivados de 2-fenilpiran-4-ona como inhibidores de ciclooxigenasa 2 |
US6664256B1 (en) * | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
EP1431293B1 (en) * | 2001-09-26 | 2011-06-08 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivatives and drugs containing the same |
MY128945A (en) * | 2002-04-16 | 2007-03-30 | Kowa Co | Solid dispersion composition |
US7074959B2 (en) * | 2002-08-01 | 2006-07-11 | New Mexico Highlands University | Methods and systems for remediating hydrazine-contaminated equipment and/or surfaces |
NZ541064A (en) * | 2003-03-07 | 2007-09-28 | Kowa Co | Benzofuran derivative |
CA2518227A1 (en) * | 2003-03-18 | 2004-09-30 | Kowa Co., Ltd | Water-soluble phenylpyridazine derivative and medicine containing the same |
US8105630B2 (en) * | 2003-04-29 | 2012-01-31 | Kowa Co., Ltd. | Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof |
MY147403A (en) * | 2003-04-29 | 2012-11-30 | Kowa Co | Composition containing medicine extremely slightly solube in water and method for preparation thereof |
WO2005012259A1 (ja) * | 2003-07-30 | 2005-02-10 | Kowa Co., Ltd. | オステオポンチン産生抑制方法 |
EP1604988A1 (en) * | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
CN101031305A (zh) * | 2004-09-29 | 2007-09-05 | 兴和株式会社 | 类风湿性关节炎的预防和/或治疗药物 |
WO2006104172A1 (ja) * | 2005-03-29 | 2006-10-05 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
EP1920772A4 (en) * | 2005-08-31 | 2010-11-17 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR COMBATING RHEUMATOID ARTHRITIS |
WO2007044796A2 (en) * | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
EP1941911A4 (en) * | 2005-10-28 | 2011-01-12 | Kowa Co | METHOD FOR PREVENTING AND / OR TREATING RHEUMATOID ARTHRITIS |
DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
US20090203701A1 (en) * | 2006-06-29 | 2009-08-13 | Kowa Co., Ltd | Prophylactic and/or therapeutic agent for rheumatoid arthritis |
DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
EP2099770B1 (en) | 2006-12-21 | 2015-06-10 | Sloan-Kettering Institute for Cancer Research | Pyridazinones and furan-containing compounds |
MX2009008059A (es) | 2007-01-29 | 2009-08-12 | Kowa Co | Agente para tratamiento de esclerosis multiple. |
WO2008111295A1 (ja) | 2007-03-09 | 2008-09-18 | Kowa Co., Ltd. | 全身性エリテマトーデスの予防及び/又は治療剤 |
DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
DE102007041115A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
CN102603676B (zh) * | 2012-02-20 | 2014-02-12 | 徐江平 | 一种能避免呕吐反应的磷酸二酯酶4抑制剂 |
MA44674B1 (fr) | 2016-04-15 | 2020-06-30 | Abbvie Inc | Inhibiteurs de bromodomaine |
WO2018081381A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc | Pyridazine derivatives, compositions and methods for modulating cftr |
WO2021163519A1 (en) | 2020-02-14 | 2021-08-19 | Fmc Corporation | Substituted 5,6-diphenyl-3(2h)-pyridazinones for use as fungicides |
TW202222163A (zh) * | 2020-08-14 | 2022-06-16 | 瑞士商先正達農作物保護公司 | 化學方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR206496A1 (es) | 1972-07-03 | 1976-07-30 | Riker Laboratories Inc | Procedimiento para la preparacion de 2-fenoxi-4-nitro-alquil o haloalquilsulfonanilidas |
WO1983000863A1 (en) * | 1981-09-11 | 1983-03-17 | Diamond Shamrock Corp | Antiinflammatory and analgetic 4-pyridylpyridazin(2h)-3-ones |
JPH0753725B2 (ja) | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
JPH01258671A (ja) * | 1987-12-01 | 1989-10-16 | Morishita Pharmaceut Co Ltd | 5−(1h−イミダゾール−1−イル)−3(2h)−ピリダジノン誘導体 |
FI91062C (fi) | 1988-12-28 | 1994-05-10 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi |
EP0530264B1 (en) * | 1990-05-15 | 1996-10-23 | E.I. Du Pont De Nemours And Company | Arthropodicidal tetrahydropyridazines |
IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
JPH08311032A (ja) * | 1995-05-18 | 1996-11-26 | Eisai Co Ltd | α,β−不飽和ケトン誘導体 |
CA2228050A1 (en) | 1995-08-10 | 1997-02-20 | Harold G. Selnick | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
JP2001514669A (ja) | 1997-03-14 | 2001-09-11 | メルク フロスト カナダ アンド カンパニー | シクロオキシゲナーゼ−2阻害薬としてのピリダジノン類 |
ATE319691T1 (de) | 1997-08-22 | 2006-03-15 | Abbott Lab | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
CA2299300C (en) | 1997-08-22 | 2007-04-17 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors |
CA2307111C (en) * | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
TWI241295B (en) * | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
TR200101765T2 (tr) | 1998-10-27 | 2002-02-21 | Abbott Laboratories | Prostaglandin endoperoksit H sentaz biyosentez inhibitörleri |
JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−3−オン誘導体及びこれを含有する医薬 |
US6664256B1 (en) * | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
-
1998
- 1998-11-09 CA CA002307111A patent/CA2307111C/en not_active Expired - Fee Related
- 1998-11-09 EP EP98951732A patent/EP1043317B1/en not_active Expired - Lifetime
- 1998-11-09 MX MXPA00004955A patent/MXPA00004955A/es not_active IP Right Cessation
- 1998-11-09 WO PCT/JP1998/005023 patent/WO1999025697A1/ja not_active Application Discontinuation
- 1998-11-09 DK DK98951732T patent/DK1043317T3/da active
- 1998-11-09 PT PT98951732T patent/PT1043317E/pt unknown
- 1998-11-09 NZ NZ504045A patent/NZ504045A/en unknown
- 1998-11-09 ES ES98951732T patent/ES2324126T3/es not_active Expired - Lifetime
- 1998-11-09 CN CNB988113015A patent/CN1142148C/zh not_active Expired - Fee Related
- 1998-11-09 HU HU0100059A patent/HUP0100059A3/hu unknown
- 1998-11-09 EP EP08019558A patent/EP2017266A1/en not_active Withdrawn
- 1998-11-09 US US09/530,949 patent/US6348468B1/en not_active Expired - Fee Related
- 1998-11-09 DE DE69840755T patent/DE69840755D1/de not_active Expired - Lifetime
- 1998-11-09 RU RU2000115577/04A patent/RU2209813C2/ru not_active IP Right Cessation
- 1998-11-09 ID IDW20000931A patent/ID24166A/id unknown
- 1998-11-09 AU AU97626/98A patent/AU738595B2/en not_active Ceased
- 1998-11-09 BR BR9813998-3A patent/BR9813998A/pt active Search and Examination
- 1998-11-09 KR KR1020007004967A patent/KR100626605B1/ko not_active IP Right Cessation
- 1998-11-09 AT AT98951732T patent/ATE428700T1/de not_active IP Right Cessation
- 1998-11-17 TW TW087119032A patent/TW502025B/zh not_active IP Right Cessation
-
2000
- 2000-04-27 NO NO20002169A patent/NO316021B1/no not_active IP Right Cessation
-
2001
- 2001-05-24 HK HK01103597A patent/HK1032969A1/xx not_active IP Right Cessation
- 2001-11-30 US US09/996,804 patent/US20020123496A1/en not_active Abandoned
-
2004
- 2004-01-15 US US10/757,525 patent/US20040147516A1/en not_active Abandoned
- 2004-11-12 US US10/986,350 patent/US20050065155A1/en not_active Abandoned
-
2005
- 2005-08-15 US US11/203,174 patent/US20050267113A1/en not_active Abandoned
-
2006
- 2006-03-22 US US11/385,995 patent/US20060160804A1/en not_active Abandoned
- 2006-11-01 US US11/590,811 patent/US20070049595A1/en not_active Abandoned
-
2007
- 2007-04-30 US US11/741,947 patent/US20070208025A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,691 patent/US20080119474A1/en not_active Abandoned
- 2008-11-03 US US12/263,816 patent/US20090069332A1/en not_active Abandoned
-
2009
- 2009-07-06 US US12/497,797 patent/US20090270399A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2307111C (en) | Novel pyridazine derivatives and drugs containing the same as the active ingredient | |
JP4328018B2 (ja) | 新規ピリダジン誘導体及びこれを有効成分とする医薬 | |
EP1300399B1 (en) | Phenylpyridazine derivatives and drugs containing the same | |
NO328714B1 (no) | Aryl- og heteroarylpiperaziner, farmasoytiske preparater som omfatter minst en slik forbindelse, samt anvendelser av slike forbindelser til fremstilling av farmasoytiske preparater | |
JP3335132B2 (ja) | 新規ピリダジン誘導体及びこれを有効成分とする医薬 | |
CA2340230C (en) | Pyridazinone derivatives having cell adhesion inhibiting activity | |
JP2000247959A (ja) | ピリダジン−3−オン誘導体及びこれを含有する医薬 | |
CA2518227A1 (en) | Water-soluble phenylpyridazine derivative and medicine containing the same | |
KR101128372B1 (ko) | 1h-피리딘-2-온 유도체 | |
MXPA00008549A (es) | Derivados novedosos de piridazina, y medicamentos que contienen los mismos como ingredientes efectivos | |
JP2000119257A (ja) | ピリダジノン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |